Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Early Access service lets users access peer-reviewed articles well before print/regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

The Journal of Public Health in Africa is, therefore, E-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination, and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear on a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

Please cite this article as:

Submitted: 8 August 2023
Accepted: 8 August 2023

© the Author(s), 2023
Licensee PAGEPress, Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Letter to the Editor

FARMOV$ and Avacare Health Group: Advancing Public Health in Africa through World-Class Clinical Research

Dear Editor,

I am writing to highlight the critical role of FARMOV$ and Avacare Health Group, in collaboration with the University of the Free State (UFS), in advancing public health in Africa through high-quality clinical research. With a remarkable track record of over 3,000 successful clinical studies, FARMOV$ has emerged as an ideal partner for conducting research on the African continent, contributing to the development of innovative interventions to address the burden of communicable and non-communicable diseases. Africa is faced with the significant challenge of addressing both communicable and non-communicable diseases. To tackle these health challenges effectively, generating evidence through high-quality ethical research is paramount. FARMOV$, Avacare Health Group, and UFS have positioned themselves as key players in conducting clinical research in Africa, enabling the development of innovative interventions that aim to improve public health outcomes.

FARMOV$ has a rich history dating back to its founding in 1974 when it conducted its first clinical trial at the academic hospital of UFS in Bloemfontein, South Africa. Recognizing the increasing demand for clinical trial services, FARMOV$ established its independent spinoff company in 1986. In 1996, FARMOV$ moved to a state-of-the-art 10,000 square meter clinical research facility on the UFS campus, further expanding its capabilities.

The core services provided by FARMOV$ encompass comprehensive clinical research, including early pharmacology studies, pharmacokinetic/pharmacodynamic research, and Phase I-III trials across various therapeutic areas. Equipped with fully staffed wards and emergency medical equipment, FARMOV$ facilitates the smooth conduct of clinical trials. It is worth noting that FARMOV$ is the sole site in Africa equipped for manual clamp studies on insulin. FARMOV$ also houses GLP and ISO15189 accredited laboratories with cutting-edge equipment for bioanalytical services. These laboratories adhere to FDA and EMA guidelines and provide qualitative and quantitative analysis of pharmacokinetic and pharmacodynamic samples in diverse biological matrices. Moreover, FARMOV$ operates an in-house pharmacy registered with the South African Pharmacy Council, ensuring adherence to strict guidelines for dispensing and compounding activities.

The site management organization at FARMOV$ maintains a network of over 50 external sites in South Africa, with plans for expansion across Africa. This network facilitates patient access and enhances research capacity through training, equipping, and mentoring of research-naïve sites. Collaborations with UFS and other institutions further strengthen recruitment activities and expertise in different therapeutic areas.

FARMOV$ goes beyond core clinical research services and offers additional support services such as project management, medical writing, quality assurance, regulatory services, and logistics for sample handling and international shipments. These comprehensive support services ensure the efficiency and compliance of trial operations.

Access to diverse study populations is a notable strength of FARMOV$. With a database of over 4,000 healthy volunteers from various ethnic groups, including treatment-naïve patients, FARMOV$ enhances the conduct of clinical research. Collaborations with UFS and other institutions further strengthen expertise in different therapeutic areas, expanding the knowledge base for improved recruitment activities.

In conclusion, FARMOV$ and Avacare Health Group, in collaboration with UFS, play a crucial role in advancing public health in Africa through their world-class clinical research. Their commitment to high-quality ethical research, demonstrated by their successful track record and adherence to international regulations, establishes them as trusted partners in the development of innovative interventions. Through their comprehensive services, extensive networks, and dedication
to excellence, FARMOV and Avacare Health Group contribute significantly to the improvement of public health outcomes across the African continent.

Sincerely,
Werner Nel
Chief Executive Officer, FARMOV

References
1. About Us – FARMOV. [Internet] [cited 2023 Jul 10]. Available from: https://www.farmovs.com/about/

Our experience

- > 580 Assay methods
- > 4000 Database of healthy volunteers
- > 3,000 BA / BE studies
- > 49 Years of Experience
- 50 External network sites (SMO)
- 130 Full Time Employees
- Phase I – Phase III clinical trials

FARMOV Credentials